Shield-and-Amplify Nanoparticle Vaccines Retune Immunodominance for Broad Protection against SARS-CoV-2
Year: 2026
Type: article
Abstract: Antigenic variation severely constrains the durability and breadth of vaccine-induced protection against rapidly evolving viruses. Although conserved epitopes can support cross-variant immunity, antibody responses to viral glycoproteins are often biased toward exposed, mutable immunodominant epitopes, leaving conserved protective sites subdominant. We previously identified a cryptic, conserved class 5 epitope (the 6D6/7D6 epitope) on the SARS-CoV-2 receptor-binding domain (RBD) capable of eliciting broad cross-neutralization. Here, we present a modular “shield-and-amplify” nanoparticle vaccination strategy to redirect immunodominance toward this subdominant epitope. We engineered site-specific N-linked glycans─alongside the native N343 glycan to mask variable immunodominant regions while preserving accessibility to the class 5 epitope. The resulting glycan-masked RBD antigen (RGM) was displayed on p239 nanoparticles via nanobody-mediated assembly, yielding multivalent RGM@p239 immunogens. Antigenic profiling revealed that glycan shielding preserved recognition by 6D6 and 7D6 antibodies while reducing binding of representative class 1–4 antibodies by at least 80%. In immunized animals, RGM@p239 enriched 7D6-competitive serum antibodies blocking approximately 70–80% of serum binding to RGM and broadened cross-variant neutralization against 8 representative variant strains, including detectable activity against Omicron lineages. Furthermore, RGM@p239 reduced disease severity after Omicron EG.1 challenge in a hamster model. These results support a model in which glycan shielding and nanoparticle multivalency act as complementary immune-focusing modules: shielding attenuates competing responses, while multivalency amplifies responses to conserved subdominant epitopes. This study establishes a nanovaccine design strategy to address antigenic variation by focusing immunity on conserved viral vulnerabilities.
Source: ACS Nano
Institution: Xiamen University
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,500
Funders: National Natural Science Foundation of China, China Postdoctoral Science Foundation, Natural Science Foundation of Fujian Province, Xiamen University, State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Key Research and Development Program of China, Fundamental Research Funds for the Central Universities
OpenAlex ID: W7225919636
